An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease

• Drug: Placebo
  
  Orally inhaled placebo twice a day (BID) for 4 weeks
• Drug: PF-03715455
  
  680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks

• Placebo Comparator: Placebo
  
  Double blind placebo for PF-03715455
  Intervention: Drug: Placebo
• Experimental: PF-03715455
  
  Intervention: Drug: PF-03715455

Inclusion Criteria:

• Female subjects of non-childbearing potential and male subjects between the ages of 40 and 80 years, inclusive
• Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD and who meet the criteria for Stage II-III disease
• Subjects must have a smoking history of at least 10 pack-years

Exclusion Criteria:

• Current evidence or history within the previous 6 months of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data
• A COPD exacerbation requiring treatment with oral steroids or hospitalization for the treatment of COPD within 3 months of Screening